Výsledky vyhledávání - "Shelby A. Labe"

Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes

Autor: Shelby A. Labe, Xi Wang, Eric J. Lehrer, Amar U. Kishan, Daniel E. Spratt, Christine Lin, Alicia K. Morgans, Lee Ponsky, Jorge A. Garcia, Sara Garrett, Ming Wang, Nicholas G. Zaorsky

Publikováno v: Clinical Genitourinary Cancer. 20:371-380

Castration-sensitive metastatic prostate cancer is heterogeneous. Our objective is to identify metastatic prostate cancer phenotypes and their prognostic impact on survival.The National Cancer Database was queried. The Surveillance, Epidemiology, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::413dbedd86f7aeb5cdee68815d2d962a
https://doi.org/10.1016/j.clgc.2022.02.008

Zobrazit plný text záznamu

National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer

Autor: Karen E. Hoffman, Peter F. Orio, David D. Yang, Martin T. King, Paul L. Nguyen, Vinayak Muralidhar, Marie E. Vastola, D.E. Spratt, F.Y. Feng, Shelby A. Labe, Michelle D. Nezolosky, Neil E. Martin, Brandon A. Mahal, Toni K. Choueiri, Quoc-Dien Trinh

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 98:338-343

Androgen deprivation therapy (ADT) is not recommended for low-risk prostate cancer because of its lack of benefit and potential for harm. We evaluated the incidence and predictors of ADT use in low-risk disease.Using the National Cancer Database, we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::176bcf03d989c75089475c72a7f3d081
https://doi.org/10.1016/j.ijrobp.2017.02.020

Zobrazit plný text záznamu

Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance

Autor: Kent W. Mouw, Michelle D. Nezolosky, Peter F. Orio, Quoc-Dien Trinh, Paul L. Nguyen, Brandon A. Mahal, Martin T. King, David D. Yang, Shelby A. Labe, Ninjin Boldbaatar, Vinayak Muralidhar, Marie E. Vastola, Neil E. Martin

Publikováno v: Clinical genitourinary cancer. 16(3)

The safety of active surveillance (AS) for Gleason 6 favorable intermediate-risk (FIR) prostate cancer is unknown. To provide guidance, we examined the incidence and predictors of upgrading or upstaging for Gleason 6 FIR patients treated with radical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdeeb4fe87cdadf71603628e3f10f447
https://pubmed.ncbi.nlm.nih.gov/29196209

Zobrazit plný text záznamu

Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer

Autor: Ninjin Boldbaatar, Vinayak Muralidhar, Marie E. Vastola, David D. Yang, Michelle D. Nezolosky, Peter F. Orio, Brandon A. Mahal, Shelby A. Labe, Clair J. Beard, Kent W. Mouw, Paul L. Nguyen, Martin T. King, Neil E. Martin

Publikováno v: Cancer. 123(24)

BACKGROUND Conservative management of aggressive prostate cancer in the elderly without definitive therapy has been associated with a 10-year prostate cancer-specific mortality of approximately 50%. The authors examined the prevalence of definitive t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81959bf8252de94d94f7ab8200d0e3d3
https://pubmed.ncbi.nlm.nih.gov/30192374

Zobrazit plný text záznamu

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer

Autor: Michelle D. Nezolosky, Shelby A. Labe, Daniel E. Spratt, Paul L. Nguyen, Martin T. King, Brandon A. Mahal, Vinayak Muralidhar, Marie E. Vastola, Clair J. Beard, Felix Y. Feng, Quoc-Dien Trinh, Peter F. Orio, Neil E. Martin, Ninjin Boldbaatar, David D. Yang, Karen E. Hoffman

Publikováno v: European urology focus. 5(1)

It is unknown whether active surveillance can be safely offered to patients with Gleason 3+4 favorable intermediate-risk (FIR) prostate cancer.To examine the incidence and predictors of upgrading and upstaging among patients with Gleason 3+4 FIR dise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02126786bf69b1c9af1753d9b957e506
https://pubmed.ncbi.nlm.nih.gov/28753811

Zobrazit plný text záznamu

Impact of Percent Positive Biopsy Cores on Cancer-Specific Mortality for Patients with High-Risk Prostate Cancer

Autor: Peter F. Orio, Martin T. King, Michelle D. Nezolosky, Shelby A. Labe, Toni K. Choueiri, Vinayak Muralidhar, Marie E. Vastola, Neil E. Martin, Paul L. Nguyen, Ninjin Boldbaatar, Quoc-Dien Trinh, Kent W. Mouw, Brandon A. Mahal, David D. Yang

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 102:e150

A high percent positive biopsy cores (PBC), typically dichotomized at ≥50% is prognostic of worse cancer-specific outcomes for patients with low- and intermediate-risk prostate cancer (CaP). The clinical significance of ≥50% PBC for patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1022d5359312b6973cc1137f3a4b9676
https://doi.org/10.1016/j.ijrobp.2018.07.291

Zobrazit plný text záznamu

Abstract 4287: Whole-genome CRISPR/Cas9 screen of the CHK1 inhibitor prexasertib implicates FAM122A loss as a potential resistance mechanism

Autor: Hunter D. Reavis, Alan D. D'Andrea, Peter Deraska, David Kozono, Shelby A. Labe

Publikováno v: Cancer Research. 78:4287-4287

Introduction: Phase I clinical trials of the CHK1 inhibitor prexasertib have been completed in non-small cell lung cancer (NSCLC) and other cancers and several Phase I-II trials are currently recruiting. By inhibiting the G2/M and S-phase checkpoints

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e1cb26bfd3bfc81144452000d4731dda
https://doi.org/10.1158/1538-7445.am2018-4287

Zobrazit plný text záznamu

Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer

Autor: Quoc-Dien Trinh, Toni K. Choueiri, Michelle D. Nezolosky, David D. Yang, Peter F. Orio, Shelby A. Labe, Vinayak Muralidhar, Marie E. Vastola, Martin T. King, Neil E. Martin, Kent W. Mouw, Paul L. Nguyen, Brandon A. Mahal, N. Boldbaatar

Publikováno v: Journal of Clinical Oncology. 36:78-78

78 Background: A high percent positive biopsy cores (PBC), typically dichotomized at ≥50%, is prognostic of worse cancer-specific outcomes for patients with low- and intermediate-risk prostate cancer. The prognostic value of ≥50% PBC for patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d727c5b51de8f6f8e6a83163b08e6476
https://doi.org/10.1200/jco.2018.36.6_suppl.78

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání